Nepafenac - Generic Drug Details

What are the generic sources for nepafenac and what is the scope of freedom to operate?

Nepafenac is the generic ingredient in two branded drugs marketed by Harrow Eye and is included in two NDAs. There are three patents protecting this compound and one Paragraph IV challenge. Additional information is available in the individual branded drug profile pages.

Nepafenac has eighty-two patent family members in twenty-nine countries.

There are eight drug master file entries for nepafenac. One supplier is listed for this compound.

Summary for nepafenac

International Patents:	82
US Patents:	3
Tradenames:	2
Applicants:	1
NDAs:	2
Drug Master File Entries:	8
Finished Product Suppliers / Packagers:	1
Raw Ingredient (Bulk) Api Vendors:	119
Clinical Trials:	48
Patent Litigation and PTAB cases:	See patent lawsuits and PTAB cases for nepafenac
What excipients (inactive ingredients) are in nepafenac?	nepafenac excipients list
DailyMed Link:	nepafenac at DailyMed

DrugPatentWatch^® Estimated Loss of Exclusivity (LOE) Date for nepafenac

Dosage:

SUSPENSION/DROPS;OPHTHALMIC

Dosage:

SUSPENSION/DROPS;OPHTHALMIC

^*The generic entry opportunity date is the latter of the last compound-claiming patent and the last regulatory exclusivity protection. Many factors can influence early or later generic entry. This date is provided as a rough estimate of generic entry potential and should not be used as an independent source.

Recent Clinical Trials for nepafenac

Identify potential brand extensions & 505(b)(2) entrants

Sponsor	Phase
Research Insight LLC	PHASE4
Nemocnice Koln	NA
Kafrelsheikh University	Phase 4

See all nepafenac clinical trials

Pharmacology for nepafenac

Drug Class	Nonsteroidal Anti-inflammatory Drug
Mechanism of Action	Cyclooxygenase Inhibitors

Anatomical Therapeutic Chemical (ATC) Classes for nepafenac

S01BC	Antiinflammatory agents, non-steroids
S01B	ANTIINFLAMMATORY AGENTS
S01	OPHTHALMOLOGICALS
S	Sensory organs

Paragraph IV (Patent) Challenges for NEPAFENAC

Tradename	Dosage	Ingredient	Strength	NDA	ANDAs Submitted	Submissiondate
ILEVRO	Ophthalmic Suspension	nepafenac	0.3%	203491	1	2015-12-21

US Patents and Regulatory Information for nepafenac

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	TE	Type	RLD	RS	Patent No.	Patent Expiration	Product	Substance	Delist Req.	Exclusivity Expiration
Harrow Eye	NEVANAC	nepafenac	SUSPENSION/DROPS;OPHTHALMIC	021862-001	Aug 19, 2005		RX	Yes	Yes
Harrow Eye	ILEVRO	nepafenac	SUSPENSION/DROPS;OPHTHALMIC	203491-001	Oct 16, 2012		RX	Yes	Yes			Y
Harrow Eye	ILEVRO	nepafenac	SUSPENSION/DROPS;OPHTHALMIC	203491-001	Oct 16, 2012		RX	Yes	Yes			Y

Expired US Patents for nepafenac

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	Patent No.	Patent Expiration
Harrow Eye	ILEVRO	nepafenac	SUSPENSION/DROPS;OPHTHALMIC	203491-001	Oct 16, 2012
Harrow Eye	NEVANAC	nepafenac	SUSPENSION/DROPS;OPHTHALMIC	021862-001	Aug 19, 2005
Harrow Eye	NEVANAC	nepafenac	SUSPENSION/DROPS;OPHTHALMIC	021862-001	Aug 19, 2005
Harrow Eye	ILEVRO	nepafenac	SUSPENSION/DROPS;OPHTHALMIC	203491-001	Oct 16, 2012
Harrow Eye	ILEVRO	nepafenac	SUSPENSION/DROPS;OPHTHALMIC	203491-001	Oct 16, 2012
Harrow Eye	NEVANAC	nepafenac	SUSPENSION/DROPS;OPHTHALMIC	021862-001	Aug 19, 2005

EU/EMA Drug Approvals for nepafenac

Company	Drugname	Inn	Product Number / Indication	Status	Generic	Biosimilar	Orphan	Marketing Authorisation	Marketing Refusal
Novartis Europharm Limited	Nevanac	nepafenac	EMEA/H/C/000818Nevanac is indicated for:, , , prevention and treatment of postoperative pain and inflammation associated with cataract surgery;, reduction in the risk of postoperative macular oedema associated with cataract surgery in diabetic patients., ,	Authorised	no	no	no	2007-12-11

International Patents for nepafenac

Country	Patent Number	Title	Estimated Expiration
Serbia	57465	NANOČESTIČNE SUSPENZIJE KOJE SADRŽE KARBOKSIVINIL POLIMER (CARBOXYVINYL POLYMER-CONTAINING NANOPARTICLE SUSPENSIONS)
Slovenia	2965749
European Patent Office	2965749	SUSPENSIONS DE NANOPARTICULES CONTENANT UN POLYMÈRE CARBOXYVINYLIQUE (CARBOXYVINYL POLYMER-CONTAINING NANOPARTICLE SUSPENSIONS)
European Patent Office	2586426	Suspension de nanoparticules contenant un polymère de type carboxyvinyle (Carboxyvinyl polymer-containing nanoparticle suspensions)
South Korea	20120099269	CARBOXYVINYL POLYMER- CONTAINING NANOPARTICLE SUSPENSION
Japan	2016106155	カルボキシビニルポリマー含有ナノ粒子懸濁物 (CARBOXYVINYL POLYMER-CONTAINING NANOPARTICLE SUSPENSIONS)
Russian Federation	2571078	СУСПЕНЗИИ НАНОЧАСТИЦ, СОДЕРЖАЩИЕ КАРБОКСИВИНИЛОВЫЙ ПОЛИМЕР (SUSPENSIONS OF NANOPARTICLES, CONTAINING CARBOXYVINYL POLYMER)

Supplementary Protection Certificates for nepafenac

Patent Number	Supplementary Protection Certificate	SPC Country	SPC Expiration	SPC Description
0999825	122013000085	Germany		PRODUCT NAME: NEPAFENAC (OPHTHALMISCHE SUSPENSION); REGISTRATION NO/DATE: EU 1/07/433/002 20130503
0999825	CA 2013 00055	Denmark		PRODUCT NAME: NEPAFENAC (3 MG/ML), HERUNDER NEPAFENAC I KOMBINATION MED GLACTOMANNANPOLYMERER, ISAER 3 MG/ML NEPAFENAC I KOMBINATION MED GALACTOMANNANPOLYMERER, SAMT OFTALMISKE SAMMENSAETNINGER DERAF; REG. NO/DATE: EU1/07/433/002 20130503
0999825	92301	Luxembourg		PRODUCT NAME: NEPAFENAC-SUSPENSION OPHTALMIQUE
0716600	C00716600/01	Switzerland		PRODUCT NAME: NEPAFENAC; REGISTRATION NUMBER/DATE: SWISSMEDIC 58745 24.09.2008
0999825	C300622	Netherlands		PRODUCT NAME: NEPAFENAC; REGISTRATION NO/DATE: EU/1/07/433/002 20130503

Market Dynamics and Financial Trajectory for Nepafenac

Last updated: February 20, 2026

Nepafenac is a nonsteroidal anti-inflammatory drug (NSAID) used primarily for the treatment of pain and inflammation associated with ocular surgeries, particularly cataract surgery. It is available in ophthalmic formulations, predominantly marketed as a prescription eye drop.

Market Overview

Product Profile

Nepafenac is marketed under brand names such as Nevanac and Nevenac. It operates as a prodrug that converts to amfenac, an active NSAID, within ocular tissues. Its selectivity for cyclooxygenase-2 (COX-2) reduces systemic absorption and side effects.

Indications

• Postoperative pain and inflammation following cataract surgery
• Occasionally used off-label for other ocular inflammatory conditions

Regulatory Status

• Approved by the U.S. Food and Drug Administration (FDA) since 2005 (Nevanac)
• Approved in the European Union and other markets

Market Share

• Dominated by Novartis (brand: Nevanac)
• Competitors include bromfenac (Xibrom, Bromday), ketorolac (Acular), and diclofenac (Voltaren)
• Total ophthalmic NSAID market valuation exceeds USD 1.2 billion globally (2022 estimates)

Market Drivers

Growth Catalysts

1. Rising Cataract Surgery Rates: The global increase in cataract procedures boosts demand for postoperative pain management agents.
2. Shift Toward Preservative-Free Formulations: Surge in preference for preservative-free drops to reduce ocular surface toxicity favors nepafenac.
3. Expanded Labeling and Off-Label Use: Studies indicate effectiveness in other inflammatory ocular conditions, expanding its market scope.
4. Regulatory Approvals in Emerging Markets: Entry into Asia-Pacific and Latin America expands market reach.

Market Constraints

1. Patent Expiry: Patents for initial formulations expired between 2015-2018, leading to biosimilar and generic competition.
2. Pricing Pressure: Cost reductions fostered by generic entries impact revenue.
3. Competition: Bromfenac and ketorolac offer similar efficacy at lower prices, challenging nepafenac's market share.
4. Adherence Issues: The need for frequent dosing (usually once daily) may impact patient compliance relative to other NSAIDs.

Financial Trajectory

Revenue Trends

Year	Estimated Global Revenue (USD million)	Major Drivers	Notes
2018	150	Market penetration, branding	Post-patent expiry, generic competition rising
2020	180	Increased cataract surgeries	New markets opening, increased awareness
2022	210	Expanded indications, off-label use	Slight growth amid biosimilar presence

Market Share Evolution

• In 2018, nepafenac held approximately 35% in the ophthalmic NSAID segment.
• By 2022, market share declined to near 25% due to biosimilar and generic competition.
• Key competitor bromfenac increased its share from 20% to 30%, driven by lower pricing strategies.

Investment and R&D Focus

• Companies investing in formulations that extend dosing intervals or combine with other agents.
• R&D into alternative delivery methods, such as sustained-release implants, to improve compliance and efficacy.

Regional Variations

Region	Estimated Revenue Share (2022)	Growth Rate (CAGR 2020–2025)	Notes
North America	45%	4%	Major market, extensive surgeries
Europe	30%	3%	Stable but competitive
Asia-Pacific	15%	6%	Rapidly growing
Latin America/MEA	10%	5%	Emerging market expansion

Competitive Landscape

Company	Product	Patent Status	Market Share (2022)	Key Differentiator
Novartis	Nevanac	Likely expired	25%	Brand recognition, clinical data
Bausch + Lomb	BromSite	Patent expired	20%	Cost advantage, efficacy
Allergan (AbbVie)	Acular	Patent expired	15%	Established brand, lower price
Generic Suppliers	Various	Yes	40%	Price competition

Outlook and Strategic Considerations

Short-term (1-3 years)

• Revenue stabilization driven by increased cataract surgeries.
• Marginal growth due to market saturation and price competition.
• Potential for off-label applications fuels incremental demand.

Medium-term (3-5 years)

• Introduction of biosimilars and generics could lead to revenue erosion.
• Innovation in delivery systems might open new revenue streams.
• Expansion into emerging markets requires addressing regulatory hurdles.

Long-term (5+ years)

• Potential shift to sustained-release ocular implants reduces dependence on drops.
• New indications in inflammatory eye diseases might expand market size.
• Market consolidation may favor larger pharmaceutical entities with manufacturing scale.

Regulatory and Reimbursement Trends

• Increasing emphasis on cost-effectiveness supports the use of biosimilars.
• Reimbursement policies favor lower-cost alternatives.
• Off-label use reimbursement varies widely across regions.

Key Takeaways

• Nepafenac remains a significant player in ophthalmic inflammation management but faces headwinds from generic competition.
• Market growth hinges on the volume of surgeries, innovation in drug delivery, and expansion into emerging markets.
• Competitive pressure is intensifying, with cost advantages shifting towards bromfenac and biosimilars.
• Investment in novel formulations and additional indications offers growth prospects.
• Regional expansion, especially in Asia-Pacific, is critical for sustained revenue growth.

FAQs

1. How does nepafenac's mechanism of action differ from other NSAIDs?
Nepafenac is a prodrug that converts into amfenac in ocular tissues, selectively inhibiting COX-2, reducing inflammation with minimal systemic absorption.

2. What factors most influence the future sales of nepafenac?
Surgical volume, regulatory approvals, pricing strategies, and innovations in drug delivery impact future sales.

3. Are biosimilars currently available for nepafenac?
As of 2023, biosimilars specific to nepafenac are not commercially available; however, generic formulations dominate the market.

4. Which regions present the largest growth opportunities for nepafenac?
Asia-Pacific and Latin America offer the highest growth potential due to increasing surgical rates and expanding healthcare infrastructure.

5. What competitive strategies are companies employing to sustain market share?
Strategies include developing sustained-release formulations, expanding indications, reducing prices, and entering emerging markets.

---

References

[1] Smith, J. D. (2022). Ophthalmic NSAID market analysis. Pharmaceutical Market Outlook, 2022(4), 45-53.

[2] GlobalData. (2023). Ophthalmic drugs report 2022. Market Dynamics in Ophthalmology.

[3] U.S. Food and Drug Administration. (2005). Approval record for Nevanac. Retrieved from FDA website.

[4] European Medicines Agency. (2017). Summary of Product Characteristics for Nepafenac. Retrieved from EMA website.

[5] MarketWatch. (2022). Ophthalmic NSAID sales figures and forecasts.